FDA OK's glucose monitoring system

June 18, 2007

The FDA has approved DexCom Inc.'s STS-7 Continuous Glucose Monitoring System. The STS-7 System measures glucose levels every five minutes throughout a seven-day period.

The FDA has approved DexCom Inc.'s STS-7 Continuous Glucose Monitoring System. The STS-7 System measures glucose levels every five minutes throughout a seven-day period. This additional information can be used to detect trends and track patterns in glucose levels throughout the week that wouldn't be captured by finger-stick measurements alone. However, patients must still rely on the finger-stick test to decide whether additional insulin is needed. The STS-7 System uses a disposable sensor placed just below the skin in the abdomen to measure the level of glucose in the fluid found in the body's tissues (interstitial fluid). The sensor must be replaced weekly.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.